

## The Top 3 Gene-Editing Stocks to Own Right Now

Gene-editing has become one of the top investing buzzwords.

All as gene editing show progress in identifying and potentially curing diseases.

Even more impressive, according to Interesting Engineering, “researchers have already identified DNA errors as the cause of nearly 7,000 diseases. Thankfully, the growing world of genome editing could be the ‘spell-checker’ needed to detect and eventually fix these.”

In short, everyone should be excited about the potential here.

### Gene Editing Stock No. 1 – Intellia Therapeutics (NTLA)

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system.



The NTLA stock just exploded after releasing “interim data from the Phase 1 trial of its collaboration with Regeneron on an experimental therapy for transthyretin amyloidosis (ATTR) – a protein misfolding disorder,” as noted in a company press release.

“The data showed that for the six people that received a single 0.3 mg/kg dose of NTLA-2001, there was an 87% mean reduction in serum TTR, while there was a maximum 96% serum TTR reduction following a month’s treatment,” the company added.

### Gene Editing Stock No. 2 – Editas Medicine (EDIT)

Editas Medicine is one of the top names in gene-editing with several trials.

It’s working on treatments for ocular diseases such as Leber Congenital Amaurosis 10 (LCA10), Usher Syndrome, neurological diseases, B-Thalassemia, and cancer.



Just the other day, the company announced that an Independent Monitoring Committee gave the company the green light to enroll children with LCA10 into pediatric cohorts of the study. According to the company, “Both the pediatric mid-dose cohort and the adult high-dose cohort will run concurrently. For both cohorts, first dosing is expected this summer and completion is expected in the first half of 2022. EDIT-101 is under development for the treatment of Leber congenital amaurosis 10 (LCA10).”

It’s also working on EDIT-301 for sickle cell disease.

According to the company, “High levels of editing were achieved in CD34+ cells using the highly specific, Editas-engineered Cas12a RNP, leading to potentially therapeutically relevant levels of HbF expression. These findings further support our novel approach to developing EDIT-301 as a transformative, durable medicine for the potential treatment of sickle cell disease,” said Kate Zhang, Ph.D., Vice President, Biological Development, Editas Medicine.

“With the current non-clinical study results and early successful tests of manufacturability, we believe our approach may yield a safer and more effective medicine, with the possibility to change the lives of people living with sickle cell disease,” the company added.

### Gene Editing Stock No. 3 – Global X Genomics and Biotechnology ETF (GNOM)

One of the best ways to diversify your gene editing portfolio is with an ETF such as the Global X Genomics and Biotechnology ETF.



According to Global X, it “seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.”

Better, at less than \$24 a share, it offers diversification among top stocks like CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, PTC Therapeutics, Agilent Technologies, Sorrento Therapeutics, and dozens more. If you were to buy 100 shares of each stock in the ETF, it would cost you thousands of dollars. To buy 100 shares of GNOM costs \$2,600.